Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos has received EUR3.7m grant from the Flemish agency for Innovation by Science and Technology (IWT) for cystic fibrosis (CF) program.
Subscribe to our email newsletter
The three-year project ‘Disease-modifying drug discovery in cystic fibrosis’ focuses on Galapagos’ CF program based on new drug targets, with the goal to deliver a pre-clinical candidate.
Galapagos is expected to collaborate with the Center for Human Genetics at the KU Leuven on this project.
Galapagos Drug Discovery SVP Graham Dixon said that they were pleased that the IWT chooses to support these efforts.
"The collaboration with the Center for Human Genetics helps us to prioritise the new targets which could make the difference to CF patients," Dixon said.
"This grant increases the chances of delivering a pre- clinical candidate by our target date of 2013."
Galapagos is a biotechnology company specialised in the discovery and development of small molecule and antibody therapies with novel modes-of-action.